CA
NMRA icon

Centerpoint Advisors’s Neumora Therapeutics NMRA Stock Holding History

Centerpoint Advisors’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Hold
220
– – ﹤0.01% 418
2026
Q1 		$0 Hold
220
– – ﹤0.01% 412
2025
Q4 		$0 Buy
+220
New +$482 ﹤0.01% 444

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Centerpoint Advisors's NMRA Position: Q2 2026 in Review

Centerpoint Advisors held its Neumora Therapeutics (NMRA) position steady in Q2 2026 at 220 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #418.

Centerpoint Advisors first reported a position in NMRA in Q4 2025 and has held it in 3 quarters since. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • Centerpoint Advisors held 220 shares of Neumora Therapeutics worth $0 as of Q2 2026.
  • Centerpoint Advisors left its Neumora Therapeutics share count unchanged in Q2 2026.
  • Neumora Therapeutics made up ﹤0.01% of Centerpoint Advisors's portfolio in Q2 2026, its #418 holding.
  • Centerpoint Advisors first reported a position in Neumora Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Centerpoint Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.